Research & development increased 66.6%
Research & development changed +66.6% from the comparable as-filed period. The change ranks at the 82th percentile of 99 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development changed +66.6% from the comparable as-filed period. The change ranks at the 82th percentile of 99 prior comparable changes.
Operating margin changed +446 basis points from the comparable as-filed period. The change ranks at the 4th percentile of 69 prior comparable changes.
Debt changed +25.0% from the comparable as-filed period. The change ranks at the 45th percentile of 31 prior comparable changes.
Revenue changed +23.8% from the comparable as-filed period. The change ranks at the 10th percentile of 69 prior comparable changes.
Inventory / revenue changed -1123 basis points from the comparable as-filed period. The change ranks at the 20th percentile of 15 prior comparable changes.
Stock-based compensation changed +31.1% from the comparable as-filed period. The change ranks at the 49th percentile of 99 prior comparable changes.
Selling, general & administrative changed +20.8% from the comparable as-filed period. The change ranks at the 15th percentile of 26 prior comparable changes.
Operating income changed +13.7% from the comparable as-filed period. The change ranks at the 27th percentile of 99 prior comparable changes.
Inventory changed +12.8% from the comparable as-filed period. The change ranks at the 0th percentile of 22 prior comparable changes.
Net income changed +12.4% from the comparable as-filed period. The change ranks at the 22th percentile of 99 prior comparable changes.
Cash & equivalents changed +7.9% from the comparable as-filed period. The change ranks at the 26th percentile of 176 prior comparable changes.
SBC / revenue changed +70 basis points from the comparable as-filed period. The change ranks at the 10th percentile of 69 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.